Similarly, a study from the Norwegian DMARD register (36) found larger improvements, after 1 year of anti-TNF therapy, in the QOL of patients with PsA (n = 172) and AS (n = 249) compared with patients with RA (n = 847), which contributed to the better retention of patients with their treatments in the PsA (77.3%) and AS (77.5%) cohorts of the register compared with the RA cohort (65.4%). The gene discussed is TNF; the disease is rheumatoid arthritis.